In-vivo comparison of the neurotoxic potencies of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA

2016 | journal article. A publication with affiliation to the University of Göttingen.

Jump to: Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​In-vivo comparison of the neurotoxic potencies of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA​
Kutschenko, A.; Manig, A.; Reinert, M.-C.; Moennich, A. & Liebetanz, D.​ (2016) 
Neuroscience Letters627 pp. 216​-221​.​ DOI: https://doi.org/10.1016/j.neulet.2016.06.001 

Documents & Media

License

GRO License GRO License

Details

Authors
Kutschenko, Anna; Manig, Anja; Reinert, Marie-Christine; Moennich, Angelika; Liebetanz, David
Abstract
Three botulinum neurotoxin type A (BoNT/A) products, incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA, all manufactured by different methods, are employed in clinical practice. Comparing the three BoNT/A products is difficult because their concentrations and volumes differ and the precise dose equivalence ratio is not known. We aimed to compare the neurotoxic potencies by a systematic analysis of injected volume and dose. The potency of BoNT in inducing hind limb paresis was assessed by analyzing the wheel-running performance of mice. To standardize the volume, the effect of an identical dose of incobotulinumtoxinA dissolved in different volumes of saline (15,10, 5, and 2 mu l) was studied in four groups of mice (n = 13-15). The potencies of the BoNT products were then compared by injecting identical volumes (10 mu l) containing different doses into both hind leg muscles. Mice injected with incobotulinumtoxinA showed a volume-dependent reduction in wheel-running, with larger volumes inducing more intense paresis. A standardized volume containing the same number of mouse units of the BoNT/A products produced different degrees of paresis. The conversion ratio of incobotulinumtoxinA and onabotulinumtoxinA is estimated to be between 1:0.75 and 1:0.5. OnabotulinumtoxinA displayed a two-fold greater potency than abobotulinumtoxinA. Doses of onabotulinumtoxinA and abobotulinumtoxinA that produce an identical severity of pareses even result in the same duration of pareses. This wheel-running assay allows one to compare the neurotoxic potency of different volumes and doses of the BoNT products in vivo. Our results argue against common clinical practice because incobotulinumtoxinA and onabotulinumtoxinA are not readily interchangeable and a two-fold dose of abobotulinumtoxinA is needed to induce an effect identical to onabotulinumtoxinA. In addition, this emphasizes that the duration of BoNT-induced effect is the same as long as equipotent doses of BoNT are injected. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
Issue Date
2016
Status
published
Publisher
Elsevier Ireland Ltd
Journal
Neuroscience Letters 
ISSN
1872-7972; 0304-3940

Reference

Citations


Social Media